Following on from information provided to NICE by the company in May 2023 the appraisal of Sintilimab with pemetrexed and platinum-based chemotherapy for untreated advanced non-squamous non-small-cell lung cancer [ID4050] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 4050
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 27 May 2023 | Discontinued. Following on from information provided to NICE by the company in May 2023 the appraisal of Sintilimab with pemetrexed and platinum-based chemotherapy for untreated advanced non-squamous non-small-cell lung cancer [ID4050] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 27 May 2022 | Note added to the project documents |
For further information on our processes and methods, please see our CHTE processes and methods manual